Please assess the completion status of the following clinical trial:

Trial Title: Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C, genotype 4-infection (hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] level greater than 1,000 IU/mL at Screening)~* Subjects must meet one of the following:~  * Treatment-naive: Subject has never received antiviral treatment for HCV infection OR~ * Treatment Experienced (Prior null responders, Partial responders or Relapsers to pegylated-interferon \[pegIFN\]/RBV);~* Females must be post-menopausal, of non-child bearing potential or practicing specific forms of birth control~* In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver biopsy or Fibroscan~* In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan with Child-Pugh score less than or equal to 6 at Screening and confirmed absence of hepatocellular carcinoma~Exclusion Criteria:~* Females who are pregnant or breastfeeding~* Positive screen for hepatitis B Surface antigen or anti-Human Immunodeficiency virus antibody~* HCV genotype performed during screening indicating unable to genotype or co-infection with any other HCV genotype~* abnormal laboratory tests~* self-reports current drinking more than 2 drinks per day~* current enrollment in another investigational study~* previous treatment with a direct acting antiviral agent (DAA) containing regimen~* In substudy 1, evidence of liver cirrhosis~* In substudy 2, evidence of current or past Child-Pugh B or C classification and confirmed presence of hepatocellular carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent \[DAA\]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
- Arm B (Type: ACTIVE_COMPARATOR): ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
- Arm C (Type: ACTIVE_COMPARATOR): ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).